Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | MPO | P05164 | 3/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | LIPC | P11150 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384644 | 0.84 | LRRK2 (0.36) | IRAK4MPOKCNH2LIPCNR1H2 | |
| SCHEMBL24896803 | 0.84 | LRRK2 (0.36) | IRAK4MPOKCNH2LIPCNR1H2 | |
| SCHEMBL24896674 | 0.83 | MPO (0.43) | MPOKCNH2NR1H2NR1H3 | |
| SCHEMBL30384462 | 0.83 | MPO (0.43) | MPOKCNH2NR1H2NR1H3 | |
| SCHEMBL30192707 | 0.83 | MPO (0.48) | MPOKCNH2NR1H2NR1H3 | |
| SCHEMBL24897015 | 0.83 | MPO (0.48) | MPOKCNH2NR1H2NR1H3 | |
| SCHEMBL24896806 | 0.83 | MPO (0.34) | IRAK4MPOHSD11B1KCNH2LIPC | |
| SCHEMBL30384591 | 0.83 | MPO (0.34) | IRAK4MPOHSD11B1KCNH2LIPC | |
| SCHEMBL30192579 | 0.81 | LRRK2 (0.34) | MPOKCNH2NR1H2NR1H3 | |
| SCHEMBL26453122 | 0.81 | LRRK2 (0.34) | MPOKCNH2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | IRAK4 1492/4885MPO 814/4885HSD11B1 935/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | IRAK4 1492/4885MPO 814/4885HSD11B1 935/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | IRAK4 1316/4885MPO 630/4885HSD11B1 864/4885 |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | F12, C1R, MRPL21 | IRAK4 1492/4885MPO 814/4885HSD11B1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.